Unlock full details of this profile with our free Lite plan!
Sign Up and Get Free AccessChimerix - About the company
Chimerix is an acquired company based in Durham (United Kingdom), founded in 2002. It operates as a Developer of antiviral oral therapeutics. Chimerix has raised $95.2M in funding from investors like New Leaf Venture Partners, Alta Partners and Morningside. The company has 839 active competitors, including 288 funded and 201 that have exited. Its top competitors include companies like Adaptive Biotechnologies, BridgeBio and Spark Therapeutics.
Company Details
Developer of antiviral oral therapeutics. The product pipeline includes Brincidofovir for smallpox, ONC201 for mutant glioma, DSTAT for acute myeloid leukemia, and ONC206 for solid tumors. It improves the quality of life for patients in multiple settings, including transplant, oncology, acute care, and global health.
- Website
- www.chimerix.com/
- Social
Key Metrics
Founded Year
2002
Location
Durham, United Kingdom
Stage
Acquired
Total Funding
$95.2M in 5 rounds
Latest Funding Round
Investors
Ranked
14th among 839 active competitors
Annual Revenue
$324K as on Dec 31, 2023
Employee Count
72 as on Dec 31, 2023
Investment & Acquisitions
Exit Details
Acquired by Jazz Pharmaceuticals (Mar 05, 2025)
Legal entities associated with Chimerix
Chimerix is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Apr 06, 2000 | $324K (as on Dec 31, 2023) | 72 (as on Dec 31, 2023) | - | |
Dec 26, 999 | - | 88 (as on Dec 31, 2022) | - |
Get your free copy of Chimerix's company profile
Chimerix's acquisition details
Chimerix got acquired by Jazz Pharmaceuticals on Mar 05, 2025 at an acquisition amount of $935M.
Click here to take a look at Chimerix's acquisition in detail
Chimerix's funding and investors
Filter this listChimerix has raised a total funding of $95.2M over 5 rounds. Its first funding round was on Nov 04, 2004.
Chimerix has 14 institutional investors including New Leaf Venture Partners, Alta Partners and Morningside.
Here is the list of recent funding rounds of Chimerix:
Date of funding | Funding Amount | Round Name | Post money valuation | Revenue multiple | Investors |
|---|---|---|---|---|---|
Nov 2014 | $122M | Post IPO | 4855201 | 2012088 | - |
Feb 14, 2011 | $45M | Series F | 5733541 | 3030416 | |
Jul 31, 2009 | $16.1M | Series E | 2726869 | 8181390 |
Access funding benchmarks and valuations. Sign up today!View details of Chimerix's funding rounds and investors
Chimerix's founders and board of directors
Founder? Claim ProfileChimerix's employee count trend
Chimerix has 72 employees as of Dec 23. Here is Chimerix's employee count trend over the years:Uncover Chimerix's growth story! Sign up today!Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Chimerix's Competitors and alternates
Top competitors of Chimerix include Adaptive Biotechnologies, BridgeBio and Spark Therapeutics. Here is the list of Top 10 competitors of Chimerix, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Overall Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Adaptive Biotechnologies 2009, Seattle (United States), Public | Provider of clinical diagnostics, and drug discovery for immune diseases | $419M | 78/100 | |
2nd | BridgeBio 2015, Palo Alto (United States), Acquired | Developer of therapeutics for the treatment of genetic diseases | $434M | 77/100 | |
3rd | Spark Therapeutics 2013, Philadelphia (United States), Acquired | Developer of gene therapy for rare diseases | $82.8M | 75/100 | |
4th | Alnylam 2002, Cambridge (United States), Public | Developer of RNA interference-based therapeutics for multiple disorders | $17M | 73/100 | |
5th | Dynavax 1996, Berkeley (United States), Public | Developer of products to prevent and treat infectious and inflammatory diseases and cancer | $73.9M | 72/100 | |
6th | Insitro 2018, San Francisco (United States), Series C | Developer of an AI-enabled technology platform for the treatment of infectious disease | $643M | 71/100 | |
7th | Ultragenyx 2010, Novato (United States), Acquired | Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases | $135M | 69/100 | |
8th | Forge Biologics 2020, Columbus (United States), Acquired | Developer of gene therapeutic solutions for treating multiple diseases | $330M | 69/100 | |
9th | Intellia Therapeutics 2014, Cambridge (United States), Public | Developer of therapeutics based on CRISPR/Cas9 technology for multiple diseases | $85M | 68/100 | |
10th | Sana Biotechnology 2018, Seattle (United States), Public | Developer of genetically engineered cell therapies for multiple disorders | $821M | 67/100 | |
14th | Chimerix 2002, Durham (United Kingdom), Acquired | Developer of antiviral oral therapeutics | $95.2M | 66/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Chimerix's competitors? Click here to see the top ones
Chimerix's Investments and acquisitions
Chimerix has acquired Oncoceutics. Chimerix has not made any investments as of now.
Reports related to Chimerix
Here is the latest report on Chimerix's sector:
News related to Chimerix
Filter this listMedia has covered Chimerix for a total of 73 events in the last 1 year, 2 of them have been about company updates.
•
Jazz Pharmaceuticals Completes Acquisition of ChimerixJazz Pharmaceuticals•Apr 21, 2025•Jazz Pharmaceuticals, Chimerix
•
Jazz Pharmaceuticals to Acquire Chimerix in Q2 2025boerse-express.com•Apr 19, 2025•Jazz Pharmaceuticals, Chimerix
•
•
Rosalind Advisors Inc. Invests $10.61 Million in Chimerix, Inc. (NASDAQ:CMRX)MarketBeat•Mar 23, 2025•Rosalind Advisors, Chimerix
•
Chimerix Reports Fourth Quarter and Year End 2024 Financial ResultsGlobeNewswire•Mar 21, 2025•Chimerix
•
Chimerix GAAP EPS of -$0.25 beats by $0.01, revenue of $0.06M misses by $0.25MSeeking Alpha•Mar 21, 2025•Chimerix
•
Halper Sadeh LLC Investigates BRDG, CMRX, WBA, CKPT on Behalf of ShareholdersPR Newswire•Mar 17, 2025•Halper Sadeh, Bridge Investment Group, Apollo Global Management, Chimerix and 5 others
•
Halper Sadeh LLC Investigates RDFN, BLBX, CMRX, WBA on Behalf of ShareholdersBenzinga•Mar 13, 2025•Redfin, Black Box Stocks, Halper Sadeh, Chimerix and 1 other
•
Halper Sadeh LLC Investigates BRDG, CMRX, WBA on Behalf of ShareholdersBenzinga•Mar 12, 2025•Halper Sadeh, Bridge Investment Group, Chimerix, Walgreens Boots Alliance
•
Halper Sadeh LLC Investigates CMRX, WBA, BLUE on Behalf of ShareholdersPR Newswire•Mar 11, 2025•Halper Sadeh, Chimerix, Walgreens Boots Alliance, Bluebird Bio
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQ's about Chimerix
Explore our recently published companies
- Fexo - Bengaluru based, 2024 founded, Unfunded company
- Viewgate Networks - Alexandria based, 1993 founded, Funding Raised company
- Brook Biotechnologies - Unfunded company
- Cretso - Mumbai based, 2021 founded, Unfunded company
- Synchron Voice and Video - Minneapolis based, 2003 founded, Public company
- Home Kouzina - Nashik based, 2021 founded, Unfunded company